Activation of an AKT/FOXM1/STMN1 pathway drives resistance to tyrosine kinase inhibitors in lung cancer

BACKGROUND: Tyrosine kinase inhibitors (TKIs) have demonstrated clinical benefits in the treatment of several tumour types. However, the emergence of TKI resistance restricts the therapeutic effect. This study uses non-small cell lung cancer (NSCLC) to explore the mechanisms contributing to TKI resi...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Br J Cancer
Autors principals: Li, Meng, Yang, Jingyu, Zhou, Wenlong, Ren, Yong, Wang, Xiaoxuan, Chen, Huiping, Zhang, Jingyuan, Chen, Junli, Sun, Yuhong, Cui, Lijuan, Liu, Xing, Wang, Lihui, Wu, Chunfu
Format: Artigo
Idioma:Inglês
Publicat: Nature Publishing Group 2017
Matèries:
Translational Therapeutics
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5625681/
https://ncbi.nlm.nih.gov/pubmed/28850563
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2017.292
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars